Rades D - Search Results

1

TRIM24 Expression as an Independent Biomarker for Prognosis and Tumor Recurrence in HNSCC.

Klapper L, Idel C, Kuppler P, Jagomast T, von Bernuth A, Bruchhage KL, Rades D, Offermann A, Kirfel J, Perner S, Ribbat-Idel J. Klapper L, et al. Among authors: rades d. J Pers Med. 2022 Jun 17;12(6):991. doi: 10.3390/jpm12060991. J Pers Med. 2022. PMID: 35743773 Free PMC article.

2

Prognostic impact of VEGF and FLT-1 receptor expression in patients with locally advanced squamous cell carcinoma of the head and neck.

Seibold ND, Schild SE, Bruchhage KL, Gebhard MP, Noack F, Rades D. Seibold ND, et al. Among authors: rades d. Strahlenther Onkol. 2013 Aug;189(8):639-46. doi: 10.1007/s00066-013-0341-2. Epub 2013 Jun 9. Strahlenther Onkol. 2013. PMID: 23748230 Clinical Trial.

3

Fibroblast growth factor 2 is of prognostic value for patients with locally advanced squamous cell carcinoma of the head and neck.

Rades D, Seibold ND, Gebhard MP, Noack F, Bruchhage KL, Schild SE. Rades D, et al. Strahlenther Onkol. 2014 Jan;190(1):68-74. doi: 10.1007/s00066-013-0368-4. Epub 2013 Jul 18. Strahlenther Onkol. 2014. PMID: 23861152

4

Androgen receptor expression: prognostic value in locally advanced squamous cell carcinoma of the head and neck.

Rades D, Seibold ND, Schild SE, Bruchhage KL, Gebhard MP, Noack F. Rades D, et al. Strahlenther Onkol. 2013 Oct;189(10):849-55. doi: 10.1007/s00066-013-0389-z. Strahlenther Onkol. 2013. PMID: 23959264

5

Re-irradiation with 36 Gy (1.5 Gy Twice Daily) Plus Paclitaxel for Advanced Recurrent and Previously Irradiated SCCHN is Feasible.

Rades D, Bartscht T, Idel C, Hakim SG. Rades D, et al. Anticancer Res. 2018 Jan;38(1):519-523. doi: 10.21873/anticanres.12253. Anticancer Res. 2018. PMID: 29277818

6

Narvaez C, Doemer C, Idel C, Setter C, Olbrich D, Ujmajuridze Z, Carl JH, Rades D. Narvaez C, et al. Among authors: rades d. BMC Cancer. 2018 Feb 17;18(1):197. doi: 10.1186/s12885-018-4119-x. BMC Cancer. 2018. PMID: 29454311 Free PMC article. Clinical Trial.

7

Hyperfractionated or Accelerated Hyperfractionated Re-irradiation with ≥42 Gy in Combination with Paclitaxel for Secondary/Recurrent Head-and-Neck Cancer.

Rades D, Bartscht T, Idel C, Schild SE, Hakim SG. Rades D, et al. Anticancer Res. 2018 Jun;38(6):3653-3656. doi: 10.21873/anticanres.12641. Anticancer Res. 2018. PMID: 29848723

8

A randomized trial (RAREST-01) comparing Mepitel® Film and standard care for prevention of radiation dermatitis in patients irradiated for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN).

Rades D, Narvaez CA, Splettstößer L, Dömer C, Setter C, Idel C, Ribbat-Idel J, Perner S, Bartscht T, Olbrich D, Schild SE, Carl J. Rades D, et al. Radiother Oncol. 2019 Oct;139:79-82. doi: 10.1016/j.radonc.2019.07.023. Epub 2019 Aug 17. Radiother Oncol. 2019. PMID: 31431372 Clinical Trial.

9

EVI1 as a Marker for Lymph Node Metastasis in HNSCC.

Idel C, Ribbat-Idel J, Kuppler P, Krupar R, Offermann A, Vogel W, Rades D, Kirfel J, Wollenberg B, Perner S. Idel C, et al. Among authors: rades d. Int J Mol Sci. 2020 Jan 28;21(3):854. doi: 10.3390/ijms21030854. Int J Mol Sci. 2020. PMID: 32013033 Free PMC article.

10

CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC.

Paulsen FO, Idel C, Ribbat-Idel J, Kuppler P, Klapper L, Rades D, Bruchhage KL, Wollenberg B, Brägelmann J, Perner S, Offermann A. Paulsen FO, et al. Among authors: rades d. Int J Mol Sci. 2020 Jul 31;21(15):5508. doi: 10.3390/ijms21155508. Int J Mol Sci. 2020. PMID: 32752128 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

593 results

Search Page